Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52330
Conference/Presentation Title: Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results.
Authors: Gaudet D.;Pall D.;Watts G.;Nicholls S. ;Rosenson R.;Modesto K.;Chang T.;Melquist S.;Fu R.;Muhsin M.A.;San Martin J.;Ballantyne C.
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Gaudet) ECOGENE-21 and Universite de Montreal, Chicoutimi, Canada
(Pall) Medical Clinical Pharmacology, University of Debrecen, Debrecen, Hungary
(Watts) School of Medicine, University of Western Australia, Perth, Australia
(Nicholls) Monash University, Victorian Heart Institute, Melbourne, Australia
(Rosenson) Mount Sinai Fuster Heart Hospital., Mount Sinai Icahn School of Medicine, New York, United States
(Modesto, Chang, Melquist, Fu, Muhsin, San Martin) Arrowhead Pharmaceuticals, Pasadena, United States
(Ballantyne) Baylor College of Medicine, Houston, United States
Presentation/Conference Date: 21-Aug-2024
Copyright year: 2024
Publisher: Elsevier Ireland Ltd
Publication information: Atherosclerosis. Conference: EAS 2024. Padova Italy. 395(Supplement 1) (no pagination), 2024. Article Number: 118459. Date of Publication: August 2024.
Journal: Atherosclerosis
Abstract: Background and Aims: Individuals with severe hypertriglyceridemia have an increased acute pancreatitis (AP) risk. Current treatments fail to lower TGs below a threshold that exposes patients to the risk of AP. Plozasiran, a hepatocyte-targeted siRNA reduces circulating TGs by interfering with the production of APOC3, a key regulator of TG metabolism. Method(s): SHASTA-2, a randomized, placebo-controlled, Phase 2b study (NCT04720534) evaluated efficacy and safety of plozasiran in patients with SHTG. Eligible patients (n=229), randomized 3:1, received a total of 2 doses (SQ 10, 25, or 50 mg plozasiran) or matched placebo on Day 1 and at Wk12 and followed through Wk48. The primary endpoint was percent change from baseline in fasting TGs at Wk24. Mixed model repeated measure (MMRM) approaches were used for statistical modeling. Result(s): Plozasiran produced LS mean reductions in APOC3 of -78% and TGs of -74% at Wk24 (p<0.0001). Reductions in APOC3 and TGs were -48% and -58% respectively at Wk48 (p <0.0001). The majority, 78% of patients achieved TGs <500 mg/dL by Wk48 vs >90% at Wk24. Durable reductions in other lipoprotein parameters (remnant cholesterol, non-HDL-C, ApoB) were also observed through Wk48. No significant increase in adverse events were reported in plozasiran treated patients. All SAEs were mild to moderate in severity (grade 1-3) and no SAEs led to discontinuation or death. Conclusion(s): Plozasiran produced highly durable TG reductions below the threshold associated with elevated AP risk. Key atherogenic lipoprotein parameters also improved. The safety profile was favorable at all doses. These data support initiation of pivotal studies of plozasiran for the treatment of SHTG.Copyright © 2024
Conference Name: EAS 2024
Conference Start Date: 2024-07-01
Conference End Date: 2024-07-05
Conference Location: Padova, Italy
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.atherosclerosis.2024.118459
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52330
Type: Conference Abstract
Subjects: acute pancreatitis
hypertriglyceridemia
liver cell
high density lipoprotein cholesterol
Type of Clinical Study or Trial: Clinical trial
Appears in Collections:Conferences

Show full item record

Page view(s)

42
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.